Clevudine

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Clevudine

Clinical data
Routes of administration	Oral
ATC code	J05AF12 (WHO) [1]
Identifiers
IUPAC name 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
CAS Number	163252-36-6 Y active moiety: 69256-17-3 Y
PubChem CID	73115
ChemSpider	65894 N
UNII	IN51MVP5F1 active moiety: 37F7D05ANB Y
KEGG	D03537 Y
ChEMBL	ChEMBL458875 N
CompTox Dashboard (EPA)	DTXSID2057659
Chemical and physical data
Formula	C10H13FN2O5
Molar mass	260.221 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)[C@H]2F)CO
InChI InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1 N Key:GBBJCSTXCAQSSJ-XQXXSGGOSA-N N
NY (what is this?)  (verify)

Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use.^[2]

It is a nucleoside analog.^[3]